736992-21-5

Usage

Uses

Used in Pharmaceutical Applications:
D-Arginyl-2,6-diMethyl-L-tyrosyl-L-lysyl-L-phenylalaninamine is used as a pharmacological agent for its potential therapeutic effects. D-Arginyl-2,6-diMethyl-L-tyrosyl-L-lysyl-L-phenylalaninaMide's unique structure and amino acid composition may contribute to its interaction with biological systems, making it a candidate for further exploration in drug development.
Used in Research and Development:
In the field of biochemistry, D-Arginyl-2,6-diMethyl-L-tyrosyl-L-lysyl-L-phenylalaninamine is used as a research compound to study the effects of peptide structure on biological activity. Its complex nature provides opportunities to investigate the role of specific amino acid arrangements and modifications in peptide function and potential applications.
Used in Diagnostic Applications:
Due to its unique properties, D-Arginyl-2,6-diMethyl-L-tyrosyl-L-lysyl-L-phenylalaninamine may be utilized in the development of diagnostic tools, such as biosensors or assays, that can detect or measure its presence or activity in biological samples. This could have implications for understanding disease mechanisms or monitoring treatment responses.
Used in Cosmetic Applications:
In the cosmetics industry, D-Arginyl-2,6-diMethyl-L-tyrosyl-L-lysyl-L-phenylalaninamine may be used as an active ingredient in skincare or beauty products. Its potential effects on skin cells and tissues could be harnessed to develop products that promote skin health, hydration, or other benefits.

Upstream product

• 35661-40-6 N-Fmoc L-Phe 
• 71989-26-9 Fmoc-Lys(tert-butoxycarbonyl) 
• 187618-60-6 N-α-[(9H-fluoren-9-ylmethoxy)carbonyl]-N^G-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-D-arginine 
• 2389-45-9 Boc-Lys(Z)-OH 
• 5241-58-7 L-Phenylalanine amide 
• 99953-00-1 (S)-N-Boc-2,6-dimethyltyrosine 
• 137764-59-1 2,6-dimethyl-N-<(phenylmethoxy)carbonyl>-L-tyrosine 
• 123715-02-6 H-Dmt 
• 17337-68-7 N^α-Benzyloxycarbonyl-lysyl(N^ε-t-butyloxycarbonyl)phenylalaninamide 
• 2389-60-8 Z-Lys(Boc)-OH 
• 17337-86-9 H-Lys(Boc)Phe-NH₂ 
• 65864-22-4 (S)-2-amino-3-phenylpropionamide hydrochloride 

Relevant academic research and scientific papers

A novel mitochondria-targeting tetrapeptide for subcellular delivery of nanoparticles

Mitochondrial dysfunction is associated with the emergence of several neurological and cardiovascular diseases. Hence, mitochondria-targeting delivery strategies are highly significant and critically needed. In this study, we developed a small library of peptides simulating the mitochondria-targeting peptide SS-31, a promising tetra-peptide with antioxidant character, and subsequently evaluated the toxicity, antioxidant ability and mitochondrial delivery of nanoparticles. Among the designed peptides, RF-2 (D-Arg-Dmt-Arg-Phe-NH2) showed controlled toxicity and excellent protection against gentamicin-induced hair cell damage, as compared with SS-31. More importantly, RF-2-modified PLGA nanoparticles demonstrated high colocalization with mitochondria and comparable specific subcellular accumulation, when compared with SS-31. Taken together, the obtained results supported RF-2 as a mitochondria-targeting peptide with high potential as a targeted carrier.

Methods and Compositions for Delivery of Biotin to Mitochondria

Certain exemplary embodiments are directed to a biologically active composition of matter (and uses thereof) configured for targeted delivery of biotin to mitochondria, the composition comprising a first D-biotin conjugated to a water-soluble, cell-permeable, peptide sequence, wherein the peptide sequence is selected from a polypeptide group with an alternating aromatic-cationic motif.

TETRAPEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME

The present invention is to provide a method for the efficient production on an industrial scale of SS-31 (D-Arg-Dmt-Lys-Phe-NH2), which is an SS peptide. According to the present invention, the desired SS-31 is produced by efficiently synthesizing a tetrapeptide compound as a precursor of SS-31 and improving the tetrapeptide purity by crystallization.

PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES

The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH2.